Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVSNovartis$121.90-1.5%$114.67$96.06▼$124.45$261.54B0.591.59 million shs955,240 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVSNovartis+0.63%+5.00%+6.12%+10.20%+16.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNVSNovartis1.6794 of 5 stars1.03.02.50.02.70.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVSNovartis 2.00Hold$123.671.45% UpsideCurrent Analyst Ratings BreakdownLatest NVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2025NVSNovartisBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVSNovartis$50.32B5.12$10.54 per share11.57$21.59 per share5.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVSNovartis$11.94B$6.4019.0513.841.7024.70%39.44%16.43%7/17/2025 (Estimated)Latest NVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/17/2025Q2 2025NVSNovartis$2.37N/AN/AN/A$13.94 billionN/A4/29/2025Q1 2025NVSNovartis$2.12$2.28+$0.16$1.83$12.92 billion$13.23 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNVSNovartis$2.602.13%N/A40.63%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVSNovartis0.560.790.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVSNovartis13.12%Insider OwnershipCompanyInsider OwnershipNVSNovartis0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNVSNovartis75,8832.11 billion2.11 billionOptionableNVS HeadlinesRecent News About These CompaniesNovartis’ hopes dashed for GCA indication for blockbuster3 hours ago | thepharmaletter.comTLate-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune Condition3 hours ago | biospace.comBNovartis drug flunks phase 3 test in giant cell arteritis3 hours ago | pharmaphorum.comPNovartis fails in late-stage trial for Cosentyx in giant cell arteritis3 hours ago | msn.comNovartis’ Blockbuster Drug Fails Late-Stage Trial In Disease Causing Blood Vessel Inflammation, But Retail Turns Bullish3 hours ago | msn.comNovartis' Cosentyx Misses Primary Goal in Arteritis Phase III StudyJuly 3 at 11:35 AM | zacks.comD.A. Davidson & CO. Sells 65,251 Shares of Novartis AG (NYSE:NVS)July 3 at 8:46 AM | marketbeat.comRossby Financial LCC Makes New $288,000 Investment in Novartis AG (NYSE:NVS)July 3 at 5:18 AM | marketbeat.comNovartis drug Cosentyx fails late-stage trial for artery diseaseJuly 3 at 2:42 AM | reuters.comNovartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)July 3 at 2:25 AM | prnewswire.comNovartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)July 3 at 2:15 AM | globenewswire.comUBS Sticks to Its Hold Rating for Novartis AG (NOVN)July 2 at 11:16 PM | theglobeandmail.comBuy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July StartJuly 2 at 10:46 AM | zacks.comProFound Therapeutics Inks $750M+ Deal with NovartisJuly 1 at 6:27 PM | contractpharma.comCNovartis AG (NVS) Hits Fresh High: Is There Still Room to Run?July 1 at 10:15 AM | zacks.comNovartis: Strong Growth and Product Performance Amid Valuation Concerns and Generic Competition RisksJuly 1 at 6:42 AM | tipranks.comEXCLUSIVE: Vamos Racquets brings padel, pickleball to former Novartis campus (updated)June 30 at 11:52 PM | njbiz.comNNovartis (NYSE:NVS) Sets New 52-Week High - Time to Buy?June 30 at 2:50 PM | marketbeat.comAltus Wealth Group LLC Purchases New Stake in Novartis AG (NYSE:NVS)June 30 at 9:03 AM | marketbeat.comNovartis AG (NYSE:NVS) Shares Sold by First Fiduciary Investment Counsel Inc.June 30 at 8:34 AM | marketbeat.comNovartis AG (NYSE:NVS) Stake Boosted by Joel Isaacson & Co. LLCJune 30 at 5:21 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVS Company DescriptionsNovartis NYSE:NVS$121.90 -1.91 (-1.54%) Closing price 03:30 PM EasternExtended Trading$123.50 +1.60 (+1.32%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
